Inhibitor Screening Kits for Immune Checkpoint Pathways

A main focal point of today’s cancer research is immune checkpoint pathway, and one of the best characterized checkpoint proteins is PD-1. The binding between PD-1 and its ligand PD-L1 suppresses T-cell activation and lets cancer cells evade the body's immune surveillance. For this reason, neutralizing PD-1 pathway activity has been considered by many oncologists to be a promising strategy.

This inhibitor screening kit contains an ELISA pair, specifically designed to facilitate the identification and characterization of new PD-1 pathway inhibitors. This assay makes use of a simple colorimetric ELISA platform to measure the binding between immobilized human PD-L1 and in-house developed biotinylated PD-1 protein. This makes the kit uniquely suitable for rapid high-throughput screening of putative PD-1 and PD-L1 inhibitors.

Assay Principle

There are 4 simple steps in this experiment:

a) Coat the plate with human PD-L1,        

b) Add biotinylated human PD-1 to bind with PD-L1, and      

c) Add your molecule of interest to the reactions,      

d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate to measure the binding activities.

To determine the ability of your compound to inhibit PD-1 : PD-L1 binding, OD readings should be compared among different experimental groups.

Immobilized human PD-L1 protein (Cat. No. A001-214) at 2 μg/mL (100 μL/well) can bind biotinylated human PD-1 (Cat. No. A002-214) with a linear range of 0.038 - 0.6 μg/mL when detected by Streptavidin-HRP (Cat. No. A003-214).

Immobilized human PD-L1 protein (Cat. No. A001-214) at 2 μg/mL (100 μL/well) can bind biotinylated human PD-1 (Cat. No. A002-214) with a linear range of 0.038 - 0.6 μg/mL when detected by Streptavidin-HRP (Cat. No. A003-214).

Inhibition of PD-1-PD-L1 binding by Anti-PD-1 neutralizing antibody (Cat. No. PD1-NA001) measured using the PD-1 [Biotinylated] : PD-L1 Inhibitor Screening ELISA Assay Pair (Cat. No. EP-101).

Inhibition of PD-1-PD-L1 binding by Anti-PD-1 neutralizing antibody (Cat. No. PD1-NA001) measured using the PD-1 [Biotinylated] : PD-L1 Inhibitor Screening ELISA Assay Pair (Cat. No. EP-101).

Product List

Cat. No. Product Description Size Price
EP-101 PD-1[Biotin]:PD-L1 Inhibitor Screening Pair ELISA Assay Pair 96 tests/480 tests $600/$2150
EP-102 CD47: SIRP alpha [Biotinylated] Inhibitor Screening ELISA Assay Pair 96 tests/480 tests $600/$2150
EP-103 PCSK9 [Biotinylated] : LDL R Inhibitor Screening ELISA Assay Pair 96 tests/480 tests $600/$2150

Fast and Easy-to-Use

ACROBiosystems eliminates the often time-consuming labeling process and greatly simplifies the experimental procedures, through the use of the pre-labeled PD-1 protein.

Authentic Human Protein Interaction

The HEK293 cells express both biotinylated PD-1 and PD-L1 proteins. By using human cells as expression host, authentic post-translational modifications essential for their binding activities are conferred.

Anti-PD1 Neutralizing Antibody Included

ACROBiosystems include anti-PD1 neutralizing mAb as a standard positive control, allowing users to validate their experiments.

High Throughput and Multiple Sizes Available

There are both 96 tests and 480 tests available as standard package sizes, for simultaneous analyses of a large amount of inhibitors.

High Detection Sensitivity and Reproducibility

The biotin labeling platform offered by ACROBiosystems produces biotinylated proteins with high detection sensitivity and minimal lot-to-lot variation. This ensures that the assay kit has desired detection sensitivity and the results are reproducible.

About ACROBiosystems

ACROBiosystems is an internationally recognized manufacturer of recombinant proteins committed to supporting cancer immunotherapy. We specialize in mammalian cell-based recombinant protein production and process development.

Our goal is to support professionals from pharmaceutical companies, CROs and research institutes who are working on the cancer immunotherapy area by providing high-quality proteins, antibodies and assay kits.

We have multiple offices and branches in North America, Europe, and Asia, and we are proud of serving customers from over 50 countries.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Jun 5, 2019 at 4:53 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ACROBiosystems. (2019, June 05). Inhibitor Screening Kits for Immune Checkpoint Pathways. News-Medical. Retrieved on July 19, 2019 from https://www.news-medical.net/whitepaper/20190529/Inhibitor-Screening-Kits-for-Immune-Checkpoint-Pathways.aspx.

  • MLA

    ACROBiosystems. "Inhibitor Screening Kits for Immune Checkpoint Pathways". News-Medical. 19 July 2019. <https://www.news-medical.net/whitepaper/20190529/Inhibitor-Screening-Kits-for-Immune-Checkpoint-Pathways.aspx>.

  • Chicago

    ACROBiosystems. "Inhibitor Screening Kits for Immune Checkpoint Pathways". News-Medical. https://www.news-medical.net/whitepaper/20190529/Inhibitor-Screening-Kits-for-Immune-Checkpoint-Pathways.aspx. (accessed July 19, 2019).

  • Harvard

    ACROBiosystems. 2019. Inhibitor Screening Kits for Immune Checkpoint Pathways. News-Medical, viewed 19 July 2019, https://www.news-medical.net/whitepaper/20190529/Inhibitor-Screening-Kits-for-Immune-Checkpoint-Pathways.aspx.

Other White Papers by this Supplier